Navigation Links
Cellular Dynamics Licenses Technology From ViaCyte

MADISON, Wis., April 13, 2011 /PRNewswire/ -- Cellular Dynamics International (CDI), the world's largest producer of tissue cells derived from human induced pluripotent stem cell (iPSC) lines, today announced it has strengthened its intellectual property (IP) portfolio by licensing patented definitive endoderm differentiation technology from ViaCyte, Inc., a stem cell company focused on diabetes therapy. CDI will apply this patented methodology in the development and production of iCell® Hepatocytes, iPSC-derived liver cells.  

ViaCyte's proprietary technology covers cell cultures containing specific amounts of definitive endoderm.  Definitive endoderm gives rise to organs and tissues such as the liver, pancreas, lung, intestine, thymus and thyroid. Separately, CDI has agreed to supply iPSC lines to ViaCyte.

Nick Seay, Chief Technology Officer of CDI, acknowledged the importance of this technology to CDI's IP portfolio. "ViaCyte has developed and filed patents on useful methodologies for differentiating into definitive endoderm, which is the normal intermediate in the subsequent manufacturing of hepatocytes. The right to incorporate this technology into our industrial pipeline assures our pharmaceutical customers that they will receive hepatocytes in the quantity, quality and purity that they require. In addition, this brings us a step closer toward developing hepatocyte line extensions, including panels with multiple iPSC starting materials. This step enables our customers to compare responses of tissue cells based on genetic diversity."

"We are pleased to strike this license agreement with CDI," said  John West, Chief Executive Officer of ViaCyte. "Our proprietary technology will facilitate the production of their iPSC-derived hepatocytes. We also look forward to using CDI's human iPSC-derived cells in the generation of pancreatic beta cells, the cells that make insulin, as our research efforts continue in our work on developing stem cell therapies for diabetes treatment."

"This licensing agreement is an important achievement for CDI as we move towards expanding our product line to include hepatocytes," added Chris Parker, Chief Commercial Officer of CDI. "The availability of these liver cells will provide pharmaceutical companies with a reliable source of well-characterized, highly reproducible and readily available human hepatocytes for preclinical drug discovery, hepatotoxicity testing, and disease research."

Terms of the licensing agreement were not disclosed.

About ViaCyte, Inc.

ViaCyte is a preclinical therapeutic company focused on diabetes. Our therapy is based on pancreatic beta cell progenitors (Pro-Islet™) derived from human pluripotent stem cells. These cells are implanted using a durable and retrievable encapsulation device. Once implanted and matured, these cells secrete insulin in response to blood glucose levels. The Company's goal is long term insulin independence without immune suppression, and without hypoglycemia and other diabetes-related complications.

ViaCyte is a private company headquartered in San Diego, California, with additional operations in Athens, Georgia. The Company is funded in part through the support of the California Institute for Regenerative Medicine.

This news release may contain forward-looking statements made pursuant to the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995.  

About Cellular Dynamics International, Inc.

Cellular Dynamics International, Inc. (CDI) is a leading developer of next-generation stem cell technologies for drug development and personalized medicine applications. CDI harnesses the power of pluripotent stem cells and their ability to differentiate into any cell type for world-class drug development tools. In addition, it is the leader in iPSC technology, the production of pluripotent stem cell-derived lines from adult tissue. CDI was founded in 2004 by Dr. James Thomson, a pioneer in human pluripotent stem cell research at the University of Wisconsin-Madison. CDI's facilities are located in Madison, Wisconsin. See

SOURCE Cellular Dynamics International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Cellular Dynamics International Scientists Report on Efficient Method to Produce Footprint-Free Induced Pluripotent Stem Cells (iPSCs) Under Feeder-Free Conditions
2. Summer Street Research Partners Closes Financing for ImmunoCellular Therapeutics, Ltd.
3. Cellular Dynamics International to Present at 29th Annual JPMorgan Healthcare Conference
4. Intra-Cellular Therapies Announces Positive Results with ITI-002 in Pre-Clinical Models of Parkinsons Disease
5. International Society for Cellular Therapy (ISCT) joins forces with Roche and Genzyme to launch Cell Therapy Industry Partnership.
6. Aegera Therapeutics Reports Survival Data from the Phase 1 Portion of its Phase 1-2 Study of AEG35156 in Combination with Sorafenib in Patients with Advanced Hepatocellular Carcinoma
7. Human Embryonic-Like Extracellular Matrix Significantly Inhibits Tumor Growth and Cancer Cell Proliferation
8. Promega and Cellular Dynamics Partner to Validate Stem Cell-Based In Vitro Assays for Predicting Drug-Induced Cardiotoxicity
9. Tengion Presents New Data Supporting Key Urologic and Kidney Programs at 16th Annual Meeting of the International Society for Cellular Therapy
10. t2cure First Company to Have Quality of Cellular Therapeutic Certified by EMA
11. iPierian Awarded Basic Biology Grant by California Institute of Regenerative Medicine to Study Cellular Reprogramming
Post Your Comments:
(Date:11/24/2015)... , November 24, 2015 ... market research report "Oligonucleotide Synthesis Market by Product & ... Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & ... by MarketsandMarkets, the market is expected to reach USD ... 2015, at a CAGR of 10.1% during the forecast ...
(Date:11/24/2015)... Nov. 24, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that ... 2015 at 11:00 a.m. Israel time, at the ... Yigal Allon Street, 36 th Floor, Tel Aviv, Israel ... Paneth and Izhak Tamir to the Board of Directors; ... external directors; , approval of an amendment to certain terms of ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... Technologies, Inc., on being named to Deloitte's 2015 Technology Fast 500 list of ... OrthoAccel manufactures AcceleDent®, a FDA-cleared, Class II medical device that speeds up orthodontic ...
(Date:11/24/2015)... , November 24, 2015 , ... a European healthcare fund ... companies will work closely together in identifying European breakthrough technologies ... need. The collaboration is underpinned by a significant investment by ... is the first investment by Bristol-Myers Squibb in a European ...
Breaking Biology Technology:
(Date:11/17/2015)... , November 17, 2015 ... au 19 novembre  2015.  --> Paris ... --> DERMALOG, le leader de l,innovation biométrique, ... la fois passeports et empreintes sur la même surface ... les passeports et l,autre pour les empreintes digitales. Désormais, ...
(Date:11/16/2015)... , Nov 16, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced expansion of its TDDI ... touch controller and display driver integration (TDDI) ... smartphones. These new TDDI products add to the ... resolution), TD4302 (WQHD resolution), and TD4322 (FHD resolution) ...
(Date:11/12/2015)... --  Growing need for low-cost, easy to use, ... the way for use of biochemical sensors for ... clinical, agricultural, environmental, food and defense applications. Presently, ... applications, however, their adoption is increasing in agricultural, ... on improving product quality and growing need to ...
Breaking Biology News(10 mins):